Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.41 |
| ▸ | AKT1S1 | Q96B36 | 5/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | NNMT | P40261 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.30 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.30 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.30 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL580706 | 0.88 | NNMT (0.37) | NNMT | |
| SCHEMBL17041865 | 0.78 | UHRF1 (0.55) | UHRF1AKT1S1NOS3NOS1NOS2 | |
| SCHEMBL23085984 | 0.77 | UHRF1 (0.41) | UHRF1AKT1S1NOS3NOS1NOS2 | |
| SCHEMBL16196456 | 0.77 | UHRF1 (0.41) | UHRF1AKT1S1NOS3NOS1NOS2 | |
| SCHEMBL23089693 | 0.77 | UHRF1 (0.41) | UHRF1AKT1S1NOS3NOS1NOS2 | |
| SCHEMBL1330038 | 0.77 | UHRF1 (0.41) | UHRF1AKT1S1NOS3NOS1NOS2 | |
| SCHEMBL1328354 | 0.74 | UHRF1 (0.36) | UHRF1AKT1S1 | |
| SCHEMBL16019530 | 0.73 | UHRF1 (0.41) | UHRF1AKT1S1NOS3NOS1NOS2 | |
| SCHEMBL797186 | 0.73 | UHRF1 (0.41) | UHRF1AKT1S1NNMTPARP1 | |
| SCHEMBL783097 | 0.73 | UHRF1 (0.41) | UHRF1AKT1S1NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4186897-A1 | PYRIDINECARBOXAMIDE COMPOUND USEFUL AS PIM KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-4186897-A1 | PYRIDINECARBOXAMIDE COMPOUND USEFUL AS PIM KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-3670506-B1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-3670506-B1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-108715590-B | Thiazolecarboxamide and picolinamide compounds useful as PIM kinase inhibitors | 因赛特公司 | 2022-03-08 | — | — | CN | disclosed |
| US-11229631-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2022-01-25 | — | — | US | disclosed |
| US-11229631-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2022-01-25 | — | — | US | disclosed |
| US-20200405702-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2020-12-31 | — | — | US | disclosed |
| US-20200405702-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2020-12-31 | — | — | US | disclosed |
| US-10828290-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| US-7560551-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560551-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1984353-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007087276-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185111-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | UHRF1 2027/4885AKT1S1 346/4885NOS3 3942/4885 |
| US-20200405702-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM2, PIM1, PIM3 | UHRF1 3897/4885AKT1S1 2142/4885NOS3 3634/4885 |
| US-11229631-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | PIM2, PIM1, PIM3 | UHRF1 3897/4885AKT1S1 2142/4885NOS3 3634/4885 |
| US-10828290-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | PIM2, PIM1, PIM3 | UHRF1 3897/4885AKT1S1 2142/4885NOS3 3634/4885 |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, AURKB | UHRF1 1408/4885AKT1S1 305/4885NOS3 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.